n-methyladenosine has been researched along with Diabetic Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X; Lin, H; Meng, L; Peng, F; Weng, J; Wu, S | 1 |
| Chun, HJ; Guo, D; Hu, C; Hu, J; Hu, L; Li, Y; Liu, M; Peng, T; Qi, B; Ren, G; Song, L; Wang, D; Zhang, F | 1 |
2 other study(ies) available for n-methyladenosine and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA.
Topics: Adenosine; Animals; Diabetic Cardiomyopathies; Down-Regulation; Epigenesis, Genetic; Methylation; Methyltransferases; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Rats; RNA Stability; RNA-Binding Proteins; RNA, Long Noncoding | 2022 |
LncRNA Airn alleviates diabetic cardiac fibrosis by inhibiting activation of cardiac fibroblasts via a m6A-IMP2-p53 axis.
Topics: Animals; Diabetes Mellitus; Diabetic Cardiomyopathies; Fibroblasts; Fibrosis; Mice; RNA-Binding Proteins; RNA, Long Noncoding; RNA, Messenger; Tumor Suppressor Protein p53 | 2022 |